Litcius/Paper detail

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardière, Fernando Rivera, Elena Élez, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Thierry André

2022The Lancet Oncology895 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMicrosatellite instabilityColorectal cancerMedicineOncologyInternal medicineChemotherapyOpen labelDNA mismatch repairCancerMicrosatelliteRandomized controlled trialImmunotherapyBiologyGeneticsGeneAlleleGenetic factors in colorectal cancerCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies